预约演示
GSK expands Asia-Pacific reach for Trelegy Ellipta with Singapore approval
2024-04-05
上市批准临床2期
Trelegy Ellipta is approved as a maintenance treatment for COPD and asthma in the US. Image Credit: MAXSHOT.PL / Shutterstock.
Trelegy Elliptalth Sciences Authority (HSA) has expanded thCOPDbel oasthmaoSmithKline (GSK)’s Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) to include its use as a maintenance therapy for adults with asthma.
The Singapore agency also approved a new dosage strength for the inhalGlaxoSmithKlinestGSK. In 2019, HSA approvfluticasone furoateaumeclidiniumnvilanterol for relieving moderate to severe exacerbations in patients wiasthmaonic obstructive pulmonary disease (COPD). Trelegy Ellipta is approved as a maintenance treatment for COPD in multiple regions including the US, Europe and China. However, the drug has also been approved for treating asthma in a few countries such as the US.
Trelegy Ellipta pulled in £2.2bn ($2.8bn) in global sales for GSK in 2023, as per thasthmaany’s finanHSAls. The drTrelegy Elliptapected to rise, with Trelegy Ellipta expected to generate approximately $3.8bn in global schronic obstructive pulmonary disease (COPD)ysTrelegy ElliptaCOPDasthma
GlobalData is the parent company of Pharmaceutical Technology.
Last month, GSK announced plans to cPharmaceutical Technologyr eligible patients at $35 per month for its COPD and asthma medications in light of the rising drug prices in the US. Trelegy Ellipta is one of the drugs included in GSK’s programme, which will be implemented across the country no later than 1 January 2025.
See Also:GSKCOPDasthmaTrelegy ElliptaGSK
UK MHRA approves Advanz Pharma antibiotic for complex infections
Japan’s PMDA apprAdvanz Pharmas inhaled Leukine for aPAP
Another therapy looking to target both asthma and COPD populations is Amgen and AstraZeneca’s Tezspire (tezepelumab-ekko). The monoclonal antibody has been approved for treating severe asthma in multiple countries including the US. The companies are evaluating the therapy in patients with moderate to severe COPD in a placebo-controlled Phase II trial (NCT04039113). Data from the trial is expected in H1 this year.
RegeneroPMDAarmaceuticals and Sainhaled Leukineeeking approval for their monoclonal antibody, Dupixent (dupilumab) as a maintenance therapy for COPD. The US Food and Drug Administration (FDA) has set a target action date of 27 June for an approval decision. Dupixent is approved for treating atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis and prurigo nodularis.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。